Dose-Response Curve: Interventions to Prevent and Treat Radiodermatitis
Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
Dose response curve to define the security and tolerable dose to be used for prevention and
treatment of radiodermatitis in patients with breast or head and neck cancer.